Initial Disclosure. Within [***] following each Option Year, Codexis will discuss with Merck any Option Improvements which have come to be Controlled by Codexis during the applicable Option Year and which have been identified and are being practiced by Codexis in its own business operations, and will describe all such Option Improvements to Merck in sufficient detail to assist Merck in determining whether to exercise an Option with respect to such Option Improvements. Merck shall have [***] after receipt of the initial disclosure regarding such Option Improvements to request the disclosure of further information Controlled by Codexis with respect to such Option [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Execution Version Improvements (“Option Evaluation Request”). All such disclosures, whether initial or subsequent, shall be considered the Information of Codexis.
Appears in 1 contract
Sources: Platform Technology Transfer and License Agreement (Codexis Inc)
Initial Disclosure. Within [***] following each Option Year, Codexis will discuss with Merck any Option Improvements which have come to be Controlled by Codexis during the applicable Option Year and which have been identified and are being practiced by Codexis in its own business operations, and will describe all such Option Improvements to Merck in sufficient detail to assist Merck in determining whether to exercise an Option with respect to such Option Improvements. Merck shall have [***] after receipt of the initial disclosure regarding such Option Improvements to request the disclosure of further information Controlled by Codexis with respect to such Option [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Execution Version Improvements (“Option Evaluation Request”). All such disclosures, whether initial or subsequent, shall be considered the Information of Codexis.
Appears in 1 contract
Sources: Platform Technology Transfer and License Agreement (Codexis, Inc.)
Initial Disclosure. Within [***] following each Option Year, Codexis will discuss with Merck any Option Improvements which have come to be Controlled by Codexis during the applicable Option Year and which have been identified and are being practiced by Codexis in its own business operations, and will describe all such Option Improvements to Merck in sufficient detail to assist Merck in determining whether to exercise an Option with respect to such Option Improvements. Merck shall have [***] after receipt of the initial disclosure regarding such Option Improvements to request the disclosure of further information Controlled by Codexis with respect to such Option [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. - 19 – Execution Version Improvements (“Option Evaluation Request”). All such disclosures, whether initial or subsequent, shall be considered the Information of Codexis.
Appears in 1 contract